Review article

Azithromycin in Treatment of Urogenital and Sexually Transmitted Infections in Women

Zlatko Topalović ; Specijalistička ginekološka ordinacija

Abstract

A zithromycin (Sumamed, PLIVA) is an antibiotic discovered in PLIVA’s Research Institute. Thanks to its exceptional properties, it has become the best-selling antibiotic worldwide and the most prescribed antibiotic for the treatment of the most common bacterial sexually transmitted and urogenital infections. Administered in a single 1 g oral dose, azithromycin is a drug of choice for acute infections due to Chlamydia trachomatis, Ureaplasma urealyticum and Mycoplasma genitalium. At the global level, considerable progress has been made in the treatment of sexually transmitted infections thanks to the clinical use of azithromycin. However, it is clear today that there are some indications where a single 1 g dose is insufficient and that azithromycin strengths and the duration of treatment should be changed. Therefore, azithromycin is administered in a dose of 1 g/week over three weeks in persistent chlamydial infection. A three-week therapy is also recommended in pelvic inflammatory disease, most often 1 g/week over three weeks or 500 mg/day IV over 1 – 2 days, followed by oral 250 mg doses up to 7 days. The long-term administration of 1 g/week over three weeks is also indicated in postvenereal reactive arthritis and Reiter’s syndrome.

Keywords

azithromycin; pharmacokinetics; sexually transmitted infections; urogenital infections; Chlamydia trachomatis; Mycoplasma; Ureaplasma; gonorrhoea; syphilis

Hrčak ID:

89364

URI

https://hrcak.srce.hr/89364

Publication date:

23.1.2012.

Article data in other languages: croatian

Visits: 19.684 *